Ocrelizumab

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) [1][2].

Product Specifications

CAS Number

[637334-45-3]

Product Name Alternative

2H7; PRO70769; RG1594

UNSPSC

12352203

Target

CD20

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ocrelizumab.html

Purity

99.61

Solubility

H2O

Smiles

[Ocrelizumab]

Molecular Weight

(145.82 kDa)

References & Citations

[1]Torres JB, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064.|[2]Schubart A, et al. Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T-and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice (P2. 410) [J]. Neurology, 2018, 90 (15_supplement) : P2. 410.